Skip Navigation LinksHomeProductsProduct Details
Product In-Details

Lipanthyl ® 300 Capsules

Lipanthyl 300 is recommended for the treatment of hypercholesterolaemia (abnormally elevated levels of cholesterol in blood) and/or hypertriglyceridaemia (abnormally elevated levels of triglycerides).

Ingredient: Fenofibrate 300 mg
Multinational Partner: Fournier
Launch Date: January 1, 1995
Pack: Box of 3 strips each 10 capsules

Product General

Disease Area



Dyslipidemia is an abnormal amount of lipids (e.g. cholesterol and/or fat) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia.

Dyslipidemia Causes:

 Causes are classified into two groups: the Primary and secondary causes

  • Primary Causes: Overproduction and defective clearance of the cholesterols TG and LDL is the result of the mutations of single or multiple genes. The primary disorders are the common dyslipidemia causes to the children, although it may not affect in the most cases of adult dyslipidemia.
  • Secondary Causes: Adults are the most affected ones when it comes to secondary causes. The causes contribute a lot on how an adult will be affected with dyslipidemia. The sedentary lifestyle is the most essential secondary cause. The lifestyle includes excessive dietary intake of cholesterol, trans fats and saturated fats. Trans fats are the fatty acids that are either polyunsaturated or monounsaturated, in which there are added hydrogen atoms. Trans fats are usually used in a lot of processed foods.
Insert leaflet


Fenofibrate (INN) 300 mg.

Excipient cis 342 mg.


For adults only. Patients with hypercholesterolernia (type Ila) or with pure (type IV) or combined Mies fib and III) endogenous hypertrigliceridernia. - when appropriate caloric restriction alone has been unsuccessful in achieving desired lipid reduction. - more particularly when cholesterol levels are still high following dietary treatment and/or with existing associated risk factors. Dietary control should be continued as an adjunct to drug treatment. No long-term controlled trials are available to establish whether or not fenofibrate has a beneficial effect in the primary or secondary prevention of atherosclerosis related complications.


As physician directs. One 300 mg capsule daily with one of the principal meals as an adjunct to dietary measures.


1-Documents Section

Update on the clinical utility of fenofi brate in mixed dyslipidemias: mechanisms of action and rational prescribing

Effects of Short-Term Fenofibrate Treatment on Circulating Markers of Inflammation and Hemostasis in Patients with Impaired Glucose Tolerance

Fenofibrate: Metabolic and Pleiotropic Effect

* ESC/EAS Guidelines for the management of dyslipidaemias. * Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

Attached Files

ESC guidelines-dyslipidemias 2011-FT.pdf
AHA metabolic syndrome.pdf

Newsletter Sign-up

Stay connected, subscribe to our newsletter
for news and updates.


Office Address

El-Bardissi St., 2T Takseem Asmaa Fahmy St., Heliopolis,
Cairo - Egypt.
Phone:(+202) 2414-3170/1/2/3/4/5
Fax:(+202) 2414-3179